Our technology allows the gentle isolation of CTC directly from fresh whole blood with no pre-processing steps involved to provide unaltered high-quality capture material.
Easy-to-handle devices for immediate compatibility with downstream characterization and analysis techniques. The capture devices are modular and can be manufactured from a wide range of materials to adjust to end-user application.
Our technology is evolutive. We are currently developing connected systems for real-time transmission of data to accelerate clinical decision-making.
End user :
Our research use clientele are made up of academic labs and institutions, CROs, and pharmaceutical industry.
CTC-STATION© is a fully-automatized benchtop system reproducing in vivo conditions to ensure optimal capture of CTC from blood samples for subsequent analysis.
CTC-STATION© will be deployed into academic research centers, clinical research institutes, and pharmaceutical industries to accelerate the adoption process of our technology into well-established CTC workflows, limited to research purposes.
End user :
CTC-PHERESIS provides the clinician a solution for the continuous, high-volume, and direct capture of cancer cells in blood. This innovation is conceived to fit an aphaeretic device able to screen a maximum volume of patient blood directly from a peripheral vein. The large blood volume in combination with the highly specific capture devices, could lead to increased cancer cells counts and better representativeness. Facing the inadequacy of current approaches with clinical routine, CTC-PHERESIS system is designed to be portable, and compatible with standard blood-processing medical devices and consumables.
Reach out to us !
We develop solutions that meet your needs.